| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2021-05-26 | Ysios Capital (Spain) | €216 million ($260 million) | Financing round | European Investment Fund (EIF) European Guarantee Fund (EGF) Health Compartment of the Sustainable Development Umbrella Fund (SDUF) | Financing round | |
| 2021-05-13 | Splisense (IL) | $28.5 million | series B financing round | Orbimed (IL) Israel Biotech Fund (IL) Biotel Limited (USA) Integra Holdings (IL) the Cystic Fibrosis Foundation (USA) | Rare diseases - Genetic diseases - Pulmonary diseases | Series B financing round |
| 2021-05-13 | Flare Therapeutics (USA - MA) | $82 million | series A financing round | Third Rock Ventures (USA - MA) Boxer Capital (USA-CA) Nextech Invest (CH) Casdin Capital (USA-NY) Invus Financial Advisors (USA-NY) Eventide Asset Management (USA-MA) | Neurological diseases - Inflammatory diseases - Immunological diseases - Rare diseases - Genetic diseases | Series A financing round |
| 2021-03-01 | SalioGen Therapeutics (USA - MA) | $20 Million | series A financing round | PBM Capital (USA - VA) and other undisclosed investors | Cardiovascular diseases - Ophthalmological diseases | Series A financing round |
| 2021-02-11 | Ensoma (USA - MA) | $70 million | series A financing round | 5AM Ventures (USA – MA) F-Prime Capital (USA – MA) Takeda Ventures (USA – MA) Viking Global Investors (USA – CA) Cormorant Asset Management (USA – MA) RIT Capital Partners (UK) Symbiosis II (USA – MA) Alexandria Venture Investments (USA – CA) | Cancer - Oncology - Autoimmune diseases - Infectious diseases | Series A financing round |
| 2019-04-08 | Sangamo Therapeutics (USA-CA) | $136.3 million | public offering | Private placement | ||
| 2018-10-18 | Oxford Nanopore Technologies (UK) | £50 million ( $66 million ) | private placement | Amgen (USA - CA) | Technology - Services | Private placement |
| 2018-10-18 | Krystal Biotech (USA - PA) | $60.0 million | private placement | Rare diseases - Genetic diseases | Private placement | |
| 2018-10-17 | Iovance Biotherapeutics (USA - CA) | $252 million | private placement | Cancer - Oncology | Private placement | |
| 2018-10-17 | Acticor Biotech (France) | € 15.3 million | series B financing round | Newton BioCapital (Belgium) CapDecisif Management (France) Mirae Capital (South Korea) CMS Medical Venture Investment (China) A&B (China) | Cerebrovascular diseases | Series B financing round |
| 2018-10-10 | Secarna Pharmaceuticals (Germany) | grant | European Commission’s Horizon 2020 programme | Rare diseases - Fibrotic diseases - Lung diseases | Grant | |
| 2018-10-10 | Allogene Therapeutics (USA - CA) | $324.0 million | IPO | Cancer - Oncology | IPO | |
| 2018-10-10 | Allogene Therapeutics (USA - CA) | $324 million | IPO | Cancer - Oncology | IPO | |
| 2018-10-10 | Histogenics (USA - MA) | $15.4 million | private placement | Regenerative Medicine - Bone diseases | Private placement | |
| 2018-10-10 | RoslinCT (UK) Reprocell (UK) | £1.2 million | grant | Innovate UK (UK) | Technology - Services | Grant |
| 2018-10-05 | Epizyme (USA - MA) | $86.25 million | private placement | Cancer - Oncology - Rare diseases | Private placement | |
| 2018-10-05 | Alligator Bioscience (Sweden) | 500 000 SEK (€ 47 845) | grant | Vinnova, Swedish Governmental Agency for Innovation Systems (Sweden) | Cancer - Oncology | Grant |
| 2018-09-28 | KSQ Therapeutics (USA - MA) | $80 million | series C financing round | Flagship Pioneering (USA - MA) Polaris Partners (USA - MA) ARCH Venture Partners (USA - IL) Alexandria Equities (USA - CA) Baillie Gifford (UK) Cowen Healthcare Investments (USA - NY) Invus (USA - NY) Lilly Asia Ventures (China) | Cancer - Oncology - Immunological diseases - Rare diseases | Series C financing round |
| 2018-09-26 | Minoryx Therapeutics (Spain) | €21.3 million | series B financing round | Chiesi Ventures (Italy) Caixa Capital Risc (Spain) HealthEquity (Spain) Fund+ (Belgium) Idinvest Partners (France) Kurma Partners (France) Sambrinvest (Belgium) Kurma Partners (France) Ysios Capital (Spain) SFPI-FPIM, S.R.I.W | Rare diseases | Series B financing round |
| 2018-09-20 | Fate Therapeutics (USA - CA) | private placement | Cancer - Oncology - Immunological diseases | Private placement |
